{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:24:50Z","timestamp":1791822290318,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T00:00:00Z","timestamp":1379980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s11910-013-0394-8","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T02:47:12Z","timestamp":1379904432000},"source":"Crossref","is-referenced-by-count":137,"title":["Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects"],"prefix":"10.1007","volume":"13","author":[{"given":"Ralf A.","family":"Linker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"394_CR1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938\u201352.","journal-title":"N Engl J Med"},{"key":"394_CR2","first-page":"141","volume":"2011","author":"J Horssen van","year":"1812","unstructured":"van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 1812;2011:141\u201350.","journal-title":"Biochim Biophys Acta"},{"key":"394_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000008084","volume":"42","author":"P Rieckmann","year":"1999","unstructured":"Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol. 1999;42:121\u20137.","journal-title":"Eur Neurol"},{"key":"394_CR4","doi-asserted-by":"crossref","unstructured":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498\u20131504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"394_CR5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285\u201394.","journal-title":"Ann Neurol"},{"key":"394_CR6","first-page":"S16","volume":"57","author":"KP Johnson","year":"2001","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 2001;57:S16\u201324.","journal-title":"Neurology"},{"key":"394_CR7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clim.2011.02.017","volume":"142","author":"R Gold","year":"2012","unstructured":"Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol. 2012;142:44\u20138.","journal-title":"Clin Immunol"},{"key":"394_CR8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.2004.02145.x","volume":"58","author":"NHR Litjens","year":"2004","unstructured":"Litjens NHR, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004;58:429\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"394_CR9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdd.364","volume":"24","author":"D Werdenberg","year":"2003","unstructured":"Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003;24:259\u201373.","journal-title":"Biopharm Drug Dispos"},{"key":"394_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000017903","volume":"196","author":"S Hoxtermann","year":"1998","unstructured":"Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology. 1998;196:223\u201330.","journal-title":"Dermatology"},{"key":"394_CR11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","volume":"121","author":"F Treumer","year":"2003","unstructured":"Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383\u20138.","journal-title":"J Invest Dermatol"},{"key":"394_CR12","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830260916","volume":"26","author":"R Jong de","year":"1996","unstructured":"de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996;26:2067\u201374.","journal-title":"Eur J Immunol"},{"key":"394_CR13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02400.x","volume":"139","author":"HM Ockenfels","year":"1998","unstructured":"Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139:390\u20135.","journal-title":"Br J Dermatol"},{"key":"394_CR14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s004030050251","volume":"289","author":"K Asadullah","year":"1997","unstructured":"Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, et al. Influence of monomethylfumarate on monocytic cytokine formation\u2014explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res. 1997;289:623\u201330.","journal-title":"Arch Dermatol Res"},{"key":"394_CR15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","volume":"208","author":"K Ghoreschi","year":"2011","unstructured":"\u2022 Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208:2291\u2013303. This describes recent work on immunomodulatory actions of dimethyl fumarate.","journal-title":"J Exp Med"},{"key":"394_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/eji.200324174","volume":"34","author":"NH Litjens","year":"2004","unstructured":"Litjens NH, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol. 2004;34:565\u201375.","journal-title":"Eur J Immunol"},{"key":"394_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1523-1747.2001.01159.x","volume":"116","author":"K Zhu","year":"2001","unstructured":"Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001;116:203\u20138.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"394_CR18","first-page":"e00055","volume":"3","author":"SX Lin","year":"2011","unstructured":"Lin SX, Lisi L, Dello RC, Polak PE, Sharp A, Weinberg G, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011;3(2):e00055.","journal-title":"ASN Neuro"},{"key":"394_CR19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2005.05.013","volume":"166","author":"A Wierinckx","year":"2005","unstructured":"Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol. 2005;166:132\u201343.","journal-title":"J Neuroimmunol"},{"key":"394_CR20","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.4049\/jimmunol.168.9.4781","volume":"168","author":"R Loewe","year":"2002","unstructured":"Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kB\/p65 in human endothelial cells. J Immunol. 2002;168:4781\u20137.","journal-title":"J Immunol"},{"key":"394_CR21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1365-2133.2001.04220.x","volume":"144","author":"TJ Stoof","year":"2001","unstructured":"Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144:1114\u201320.","journal-title":"Br J Dermatol"},{"key":"394_CR22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/bbrc.1997.6570","volume":"234","author":"M Vandermeeren","year":"1997","unstructured":"Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun. 1997;234:19\u201323.","journal-title":"Biochem Biophys Res Commun"},{"key":"394_CR23","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","volume":"129","author":"R Gold","year":"2006","unstructured":"Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129:1953\u201371.","journal-title":"Brain"},{"key":"394_CR24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.nbd.2008.01.001","volume":"30","author":"E Herrero-Herranz","year":"2008","unstructured":"Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis. 2008;30:162\u201373.","journal-title":"Neurobiol Dis"},{"key":"394_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","volume":"145","author":"S Schilling","year":"2006","unstructured":"Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145:101\u20137.","journal-title":"Clin Exp Immunol"},{"key":"394_CR26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"\u2022\u2022 Linker RA, Lee DH, Ryan S, Van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678\u201392. This is a preclinical study revealing that dimethyl fumarate activates the Nrf2 antioxidant pathway.","journal-title":"Brain"},{"key":"394_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568007054038238","volume":"4","author":"FL Muiswinkel van","year":"2005","unstructured":"van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord. 2005;4:267\u201381.","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"394_CR28","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1073\/pnas.0700898104","volume":"104","author":"Y Liu","year":"2007","unstructured":"Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A. 2007;104:5205\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"394_CR29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1742-2094-9-163","volume":"9","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.","journal-title":"J Neuroinflammation"},{"key":"394_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","volume":"341","author":"RH Scannevin","year":"2012","unstructured":"\u2022 Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274\u201384. This describes comprehensive in vitro work on the cytoprotective role of FAE.","journal-title":"J Pharmacol Exp Ther"},{"key":"394_CR31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.freeradbiomed.2010.07.013","volume":"49","author":"J Horssen van","year":"2010","unstructured":"van Horssen J, Drexhage JA, Flor T, Gerritsen W, van der Valk P, de Vries HE. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med. 2010;49:1283\u20139.","journal-title":"Free Radic Biol Med"},{"key":"394_CR32","first-page":"103","volume":"13","author":"W Schweckendiek","year":"1959","unstructured":"Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr. 1959;13:103\u20134.","journal-title":"Med Monatsschr"},{"key":"394_CR33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-2133.1998.02124.x","volume":"138","author":"U Mrowietz","year":"1998","unstructured":"Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German multicentre study. Br J Dermatol. 1998;138:456\u201360.","journal-title":"Br J Dermatol"},{"key":"394_CR34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2133.1999.03034.x","volume":"141","author":"U Mrowietz","year":"1999","unstructured":"Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol. 1999;141:424\u20139.","journal-title":"Br J Dermatol"},{"key":"394_CR35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s001050050401","volume":"47","author":"P Altmeyer","year":"1996","unstructured":"Altmeyer P, Hartwig R, Matthes U. Das Wirkungs- und Sicherheitsprofil von Fumars\u00e4ureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Eine Untersuchung an 83 Patienten. Hautarzt. 1996;47:190\u20136.","journal-title":"Hautarzt"},{"key":"394_CR36","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMc1211805","volume":"368","author":"U Ermis","year":"2013","unstructured":"Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368:1657\u20138.","journal-title":"N Engl J Med"},{"key":"394_CR37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","volume":"368","author":"BW Oosten van","year":"2013","unstructured":"van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368:1658\u20139.","journal-title":"N Engl J Med"},{"key":"394_CR38","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","volume":"368","author":"MT Sweetser","year":"2013","unstructured":"Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368:1659\u201361.","journal-title":"N Engl J Med"},{"key":"394_CR39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","volume":"78","author":"N Schwab","year":"2012","unstructured":"Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin aLb2 in JC virus control. Neurology. 2012;78:458\u201367.","journal-title":"Neurology"},{"key":"394_CR40","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1468-1331.2006.01292.x","volume":"13","author":"S Schimrigk","year":"2006","unstructured":"Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13:604\u201310.","journal-title":"Eur J Neurol"},{"key":"394_CR41","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","volume":"372","author":"L Kappos","year":"2008","unstructured":"Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463\u201372.","journal-title":"Lancet"},{"key":"394_CR42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458511421054","volume":"18","author":"L Kappos","year":"2012","unstructured":"Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing\u2013remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler. 2012;18:314\u201321.","journal-title":"Mult Scler"},{"key":"394_CR43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00415-010-5777-z","volume":"258","author":"DG MacManus","year":"2011","unstructured":"\u2022 MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol. 2011;258:449\u201356. This provides MRI evidence for a tissue-protective effect of the dimethyl fumarate preparation BG-12 in RRMS.","journal-title":"J Neurol"},{"key":"394_CR44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"\u2022\u2022 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098\u2013107. This is a pivotal phase III study of the dimethyl fumarate preparation BG-12 in RRMS.","journal-title":"N Engl J Med"},{"key":"394_CR45","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"\u2022\u2022 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087\u201397. This is a pivotal phase III study of the dimethyl fumarate preparation BG-12 in RRMS.","journal-title":"N Engl J Med"},{"key":"394_CR46","author":"A Bar-Or","year":"2013","unstructured":"Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013. doi: 10.1007\/s00415-013-6954-7 .","journal-title":"J Neurol"},{"key":"394_CR47","author":"M Hutchinson","year":"2013","unstructured":"Hutchinson M, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013. doi: 10.1007\/s00415-013-6968-1 .","journal-title":"J Neurol"},{"key":"394_CR48","doi-asserted-by":"crossref","first-page":"e16172","DOI":"10.1371\/journal.pone.0016172","volume":"6","author":"G Ellrichmann","year":"2011","unstructured":"Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, et al. Efficacy of fumaric acid esters in the R6\/2 and YAC128 models of Huntington's disease. PLoS One. 2011;6:e16172.","journal-title":"PLoS One"},{"key":"394_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","volume":"1147","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci. 2008;1147:61\u20139.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-013-0394-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-013-0394-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-013-0394-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:28:29Z","timestamp":1559420909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-013-0394-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,24]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s11910-013-0394-8","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,24]]},"article-number":"394"}}